Ketorolac use approved for post-cataract surgery

Article

The FDA recently approved ketorolac tromethamine ophthalmic solution 0.45% (Acuvail, Allergan) for treating pain and inflammation following cataract surgery.

Key Points

Irvine, CA-The FDA recently approved ketorolac tromethamine ophthalmic solution 0.45% (Acuvail, Allergan) for treating pain and inflammation following cataract surgery.

Ketorolac, a nonsteroidal anti-inflammatory, is formulated at pH 6.8, enabling deionized drug delivery on the corneal surface. The ketorolac formulation also contains carboxymethylcellulose to enable the drug to adhere to the ocular surface to enhance patient comfort. Additionally, it inhibits COX-1 and COX-2 enzymes, which are considered the primary sources of pain and inflammation following cataract surgery.

"With its preservative-free formulation, optimized tolerability, and twice-daily dosing convenience, we anticipate that [the ketorolac formulation] will be a valuable addition to the overall management of cataract surgery patients," said Scott Whitcup, MD, Allergan's executive vice president, research and development, and chief scientific officer.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Jade Coats, OD, FAAO, gives her insight on what makes EyeCon valuable for eye care providers.
Allen, OD, FAAO, Dipl ABO, plans to talk all things ocular surface for optometrists and ophthalmologists alike.
Another drop in the presbyopia bucket: Dr Bloomenstein shares his excitement for the FDA approval of Vizz
© 2025 MJH Life Sciences

All rights reserved.